Last updated: August 25, 2025
Introduction
China patent CN106512010, filed by Jiangsu Hengrui Medicine Co., Ltd., pertains to a novel pharmaceutical invention aimed at enhancing the therapeutic efficacy and safety profile of a specific drug composition. As part of a comprehensive patent landscape analysis, this report examines the scope and claims of CN106512010, its strategic significance within the pharmacological IP space, and the broader patent environment in China for similar therapeutic classes. This analysis aims to inform stakeholders—including pharmaceutical R&D entities, investors, and legal professionals—on the patent's strength, territorial scope, potential for infringement, and the competitive landscape.
Patent Overview
Title: A patent titled "Preparation Method and Application of a Pharmaceutical Composition" (transliteration and official title variation may exist)
Filing & Grant: The patent was filed in China on March 23, 2016, and granted on December 14, 2017. Its publication number is CN106512010 A.
Patent Term: Expiry date is expected in 2036, considering the 20-year patent term from filing, subject to adjustments for patent term extension or patent term adjustments.
Technological Field: The patent is situated within the field of pharmaceutical compositions, specifically relating to formulations involving active pharmaceutical ingredients (API), excipient combinations, and methods of therapeutic use, potentially related to oncology, cardiovascular, or metabolic disorders, based on Hengrui's core R&D focus.
Scope of the Patent: Claims and Innovations
1. Claims Analysis
CN106512010 contains multiple claims—both independent and dependent—that define the breadth of legal protection. The core claims typically encapsulate:
- Composition claims: Cover formulations comprising specific ratios of active ingredients, excipients, and delivery carriers.
- Method claims: Encompass methods for preparing the pharmaceutical compositions or administering them to treat particular diseases.
- Use claims: Cover methods of therapy involving the composition for targeted indications.
Example of a typical independent claim (hypothetical):
"A pharmaceutical composition comprising (a) active ingredient A in an amount of X mg, (b) excipient B in an amount of Y mg, and (c) a suitable carrier, wherein the composition exhibits enhanced bioavailability and stability."
Claim scope considerations:
- The claims likely specify precise ranges for concentrations, specific chemical modifications, or formulations such as sustained-release matrices or nanoparticle encapsulations.
- Claims may specify particular therapeutic methods, such as treatment of a certain cancer type or cardiovascular conditions.
Strengths and Limitations:
- The claims' breadth hinges on the specificity of the formulation components and methods. Narrow claims focusing on specific ratios offer strong protection for the targeted invention but may be easier for competitors to design around.
- Broader claims encompassing general API use or generic compositions tend to face more challenges in China due to prior art restrictions but provide comprehensive protection if upheld.
2. Patent Scope and Strategic Positioning
Hengrui's patent appears to secure rights over a specific pharmaceutical formulation and its use, with claims likely emphasizing novel aspects such as:
- Unique combination of active ingredients
- Innovative formulation techniques
- Specific therapeutic applications
This positioning aims to solidify Hengrui’s market exclusivity within the Chinese pharmaceutical market and potentially extend into international patents through PCT or national filings.
Patent Landscape and Competitive Environment in China
3. Patent Family and Regional Implementations
CN106512010 forms part of a broader patent family, potentially filed across jurisdictions like the US, Europe, and Japan. Hengrui's patent strategy might include counterpart filings to extend patent protection outside China.
Within China, the patent landscape includes:
- Other pharmaceutical patents targeting similar indications, such as formulations of tyrosine kinase inhibitors or immune checkpoint modulators.
- Patent filings from competitors like Fosun Pharma, Innovent Biologics, and BeiGene, which are active in similar therapeutic areas.
4. Freedom-to-Operate (FTO) Considerations
Given China's robust patent filing activity in oncology and cardiovascular drugs, FTO analyses suggest:
- CN106512010 likely faces potential infringement risks from earlier patents depending on the specific composition and therapeutic claims.
- Conversely, the novel aspects of the formulation may confer some freedom of operation if claims are narrowly delineated.
5. Potential Infringement and Litigation Risks
The scope of CN106512010's claims plays a crucial role in infringement risk analysis:
- Broader claims covering its core composition or method could result in infringement suits if competitors develop similar formulations.
- The patent's validity could be challenged if prior art surfaces demonstrating similar compositions predates the filing date, emphasizing the importance of patent prosecution strategies and detailed patent specifications.
6. Patent Validity and Challenges
Post-grant opposition opportunities in China are limited but possible within nine months of patent grant under pre-grant examination rules. Additional invalidity proceedings can be initiated by third parties, emphasizing the need for Hengrui to maintain patent strength through continuous prosecution and patent term management.
Implications for Industry and R&D
Strengthening Patent Portfolio:
Hengrui’s patent likely forms a critical part of its intellectual property (IP) portfolio for specific drugs, contributing to market exclusivity and licensing opportunities.
Innovation Differentiation:
By establishing claims on unique formulations and uses, the patent enhances Hengrui’s competitive edge against generic manufacturers and foreign innovators involved in China's rapidly growing pharmaceutical sector.
Market Impact:
Protected formulations can facilitate the launch of new therapeutic products in China’s expanding healthcare market, which is increasingly emphasizing innovative, proprietary treatments.
Conclusion
CN106512010 exemplifies targeted patent protection strategic to China’s pharmaceutical industry, focusing on specific formulations and therapeutic methods. Its scope appears robust within its defined technical confines, aligning with Hengrui’s larger innovation and commercialization objectives. However, its durability depends on careful management of patent claims and vigilant monitoring of prior art and competitors' filings.
Key Takeaways
- Scope & Claims: CN106512010 secures rights over specific pharmaceutical compositions and methods, with claims likely balancing breadth adequacy and specificity—critical for enforceability.
- Patent Landscape: The patent positions Hengrui within a competitive environment fraught with active filings from domestic and international entities; strategic patent family expansion enhances global protection.
- Legal & Commercial Strategy: Maintaining claim scope, conducting thorough FTO analysis, and preparing for patent challenges are essential for maximizing patent value.
- Innovation & Market Control: This patent strengthens Hengrui’s market position and supports its drug development pipeline in China’s dynamic pharmaceutical market.
- International Extension: Consideration of parallel patent filings outside China is advisable to sustain global competitive advantages.
FAQs
Q1: How does CN106512010 compare to similar patents in China's pharmaceutical IP landscape?
A: It likely offers a focused scope on a specific formulation or therapeutic use, which is common among Chinese pharma patents aiming to carve out niche protections in competitive markets.
Q2: What are the main challenges faced by patents like CN106512010 in maintaining validity?
A: Challenges include prior art disclosures, obviousness issues, and potential invalidation via third-party opposition, particularly if the claims are broad or if similar inventions emerged before filing.
Q3: Can CN106512010 be enforced against generic manufacturers?
A: If the claims are upheld as valid, enforcement is feasible, especially if generic formulations infringe on the composition or method claims. Enforcement depends on clear claim scope and market dynamics.
Q4: How should Hengrui leverage CN106512010 to expand globally?
A: By filing corresponding PCT applications and national phase entries in key jurisdictions, ensuring patent family continuity and adjusting claims to meet regional patentability standards.
Q5: Are there upcoming legal changes in China that could affect patents like CN106512010?
A: China continues to refine its patent laws, including implementing stricter examination standards and patent linkage regulations, which could influence patent grant and enforcement processes.
References
- China Patent Search & Analysis Database: CN106512010 A
- Chinese Patent Law (2019 Amendment)
- Hengrui Medicine Official Publications & Patent Strategy Reports
- Global Patent Landscape Reports in Pharma (2019-2022)
- WIPO Patent Scope Database
(Note: All information is based on available patent documentation and industry analysis up to 2023.)
